Kirstin Lloyd
Internal Medicine · Phoenix, AZNPI 1548615644
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Fisher & Paykel Healthcare Inc at 54.9% of the total. 2025 is the largest year on record at $2,270, more than ten times the $159 reported in 2019. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $89.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fisher & Paykel Healthcare Inc$2K
- Inspire Medical Systems, Inc.$571
- Jazz Pharmaceuticals Inc.$523
- Harmony Biosciences LLC$190
- ZOLL Respicardia, Inc.$175
- United Therapeutics Corporation$63
- plus $329 from 16 others
What the payments were for
- Speaking & faculty fees$2,25055%
- Travel & lodging$39610%
- Food & beverage$1,25731%
- Education$1975%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FISHER & PAYKEL HEALTHCARE$11,250
- Inspire Upper Airway Stimulation System$571
- remede System$154
- Wakix$112
- XYREM$112
How this compares
$4,100 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $15,811 |
| Atorvastatin Calcium | 110 | $1,669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $926 |
| Rosuvastatin Calcium | 35 | $730 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $667 |
| Lisinopril | 67 | $480 |
| Duloxetine Hcl | 23 | $361 |
| Gabapentin | 24 | $333 |
| Omeprazole | 12 | $318 |
| Metoprolol Succinate | 16 | $282 |
| Losartan Potassium | 31 | $236 |
| Metformin Hcl | 27 | $190 |
| Montelukast Sodium | 13 | $182 |
| Levothyroxine Sodium | 26 | $181 |
| Amlodipine Besylate | 30 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $24 | $15,81111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Kelly KrohnPhoenix$262K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Nafis Shamsid-DeenPhoenix$115K
- Shishir MurarkaPhoenix$79K
- Mark WongPhoenix$71K
- Geoffrey OrmePhoenix$27K
- Roberto RuizPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.